Company / R&D per Share
Fulgent Genetics, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.75
FY2025
5-year range
$0.23 / $1.75
FY2021-FY2025
Trend
+6.2%
vs FY2024
Sector context
#54 of 108
Health Care
What the data says
At $1.75, Fulgent Genetics, Inc.'s r&d per share ranks #54 of 108 in the Health Care sector. R&D per Share has increased for 4 consecutive years, from $0.23 in FY2021 to $1.75 in FY2025.
Based on SEC 10-K filings.
1.75 in FY2025 with a 5-year CAGR of +26.5%.
Improved from $0.82 to $1.75 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +65.7%
- 5-Year CAGR
- +26.5%
- 10-Year CAGR
- -
Sector benchmark
#54 of 108 in Health CareTop 50% of 108This company $1.75 Sector average $2.07
▼
-15.7% below sector average
Key checks
Key Insights
- Fulgent Genetics, Inc.'s r&d per share has grown for 4 consecutive years.
- In FY2025, r&d per share increased 6.2% year-over-year.
- Ranks #54 out of 108 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.75 | +6.2% |
| FY2024 | $1.65 | +100.1% |
| FY2023 | $0.82 | +114.3% |
| FY2022 | $0.38 | +65.5% |
| FY2021 | $0.23 | -57.0% |
| FY2020 | $0.54 | +77.0% |
| FY2019 | $0.30 | +28.7% |
| FY2018 | $0.24 | -1.0% |
| FY2017 | $0.24 | +710.6% |
| FY2016 | $0.03 | -92.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026